1.47
1.34%
-0.02
Icad Inc stock is currently priced at $1.47, with a 24-hour trading volume of 62,830.
It has seen a -1.34% decreased in the last 24 hours and a -22.63% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.49 pivot point. If it approaches the $1.44 support level, significant changes may occur.
Previous Close:
$1.49
Open:
$1.5
24h Volume:
62,830
Market Cap:
$38.74M
Revenue:
$20.46M
Net Income/Loss:
$-4.85M
P/E Ratio:
-3.00
EPS:
-0.49
Net Cash Flow:
$-6.23M
1W Performance:
+0.00%
1M Performance:
-22.63%
6M Performance:
-5.77%
1Y Performance:
+3.52%
Icad Inc Stock (ICAD) Company Profile
Name
Icad Inc
Sector
Industry
Phone
603 882 5200
Address
98 Spit Brook Road, Suite 100, Nashua, NH
Icad Inc Stock (ICAD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-18-22 | Downgrade | Guggenheim | Buy → Neutral |
Apr-22-21 | Initiated | Guggenheim | Buy |
Mar-23-21 | Initiated | BTIG Research | Buy |
Feb-26-21 | Initiated | Oppenheimer | Outperform |
Jan-29-21 | Initiated | Cantor Fitzgerald | Overweight |
Dec-03-20 | Initiated | B. Riley Securities | Buy |
Feb-05-20 | Initiated | JMP Securities | Mkt Outperform |
Jan-09-20 | Initiated | Lake Street | Buy |
Dec-09-08 | Reiterated | Canaccord Adams | Buy |
Aug-01-08 | Reiterated | MDB Capital Group | Buy |
May-14-08 | Reiterated | Canaccord Adams | Buy |
Feb-14-08 | Initiated | Sun Trust Rbsn Humphrey | Buy |
Jan-24-07 | Reiterated | Dawson James | Speculative Buy |
View All
Icad Inc Stock (ICAD) Latest News
iCAD to Report First Quarter 2024 Financial Results on May 15, 2024
GlobeNewswire Inc.
iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium
GlobeNewswire Inc.
iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation
GlobeNewswire Inc.
iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting
GlobeNewswire Inc.
iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results
GlobeNewswire Inc.
iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings
GlobeNewswire Inc.
Icad Inc Stock (ICAD) Financials Data
Icad Inc (ICAD) Revenue 2024
ICAD reported a revenue (TTM) of $20.46 million for the quarter ending December 31, 2023, a -15.09% decline year-over-year.
Icad Inc (ICAD) Net Income 2024
ICAD net income (TTM) was -$4.85 million for the quarter ending December 31, 2023, a +64.51% increase year-over-year.
Icad Inc (ICAD) Cash Flow 2024
ICAD recorded a free cash flow (TTM) of -$6.23 million for the quarter ending December 31, 2023, a +53.26% increase year-over-year.
Icad Inc (ICAD) Earnings per Share 2024
ICAD earnings per share (TTM) was -$0.19 for the quarter ending December 31, 2023, a +64.15% growth year-over-year.
About Icad Inc
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
Cap:
|
Volume (24h):